Cetera Investment Advisers
VERA icon

Cetera Investment Advisers’s Vera Therapeutics VERA Stock Holding History

Cetera Investment Advisers’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,765
Closed -$249K – 3854
2024
Q1 		$249K Buy
+5,765
New +$205K ﹤0.01% 3193

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Cetera Investment Advisers's VERA Position: Q2 2024 in Review

Cetera Investment Advisers sold out of Vera Therapeutics (VERA) in Q2 2024, closing a stake of 5,765 shares — an estimated $249K sold.

Cetera Investment Advisers first reported a position in VERA in Q1 2024 and held it in 1 quarter. The position peaked at $249K in Q1 2024. 171 funds tracked by Wall St. Rank hold VERA as of Q2 2024.

  • Cetera Investment Advisers reported no remaining Vera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 5,765 Vera Therapeutics shares in Q2 2024, an estimated $249K.
  • Cetera Investment Advisers first reported a position in Vera Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cetera Investment Advisers's Vera Therapeutics position peaked at $249K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2024.

Based on Cetera Investment Advisers's 13F filing for Q2 2024, filed 22 Aug 2024.